This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schuller, G. B. Articles by Morahan, P. S. Search for Related Content PubMed PubMed Citation Articles by Schuller, G. B. Articles by Morahan, P. S.

Cellular and Serum Involvement in Protection against Friend Leukemia Virus¹

Departments of Surgery and Microbiology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298

Treatment of mice with the immunomodulator pyran copolymer inhibited leukemogenesis produced by Friend leukemia virus (FLV) complex, as evidenced by inhibition of the spleen focus-forming virus and lymphatic leukemia virus, as well as by a significant decrease in splenomegaly. In this report we present data suggesting that the protective effect of pyran is mediated by macrophages. Protection was conferred on normal recipient mice when peritoneal exudate cells from pyran-treated mice were transferred to recipient mice infected 24 hr later with FLV. Animals receiving pyran-activated peritoneal cells had a significant reduction of splenomegaly and of titers of spleen focus-forming virus and lymphatic leukemia virus than did control animals. In contrast, when glycogen-elicited peritoneal exudate cells were transferred, the mice were not protected. Pyran-activated peritoneal cells, but not normal peritoneal cells, also inhibited FLV growth in vitro. Serum from pyran-treated, but not glycogen-treated, mice also transferred resistance to FLV-infected mice.

¹ This study was supported by NIH Grants CA10537, CA16193, and A100382. A portion of the work was presented at the Annual Meeting of the American Society for Microbiology, May 1976 (29).

² Recipient of USPHS Research Career Development Award A170863. To whom correspondence should be addressed.

Received 5/ 9/77. Accepted 7/26/77.